



2012

Progress Towards A Facile Synthesis of a Gadolinium (III) Octabrominated Porphyrin

Tseng Xiong
Georgia College & State University

Follow this and additional works at: <https://kb.gcsu.edu/thecorinthian>



Part of the [Inorganic Chemistry Commons](#)

Recommended Citation

Xiong, Tseng (2012) "Progress Towards A Facile Synthesis of a Gadolinium (III) Octabrominated Porphyrin," *The Corinthian*: Vol. 13 , Article 6.

Available at: <https://kb.gcsu.edu/thecorinthian/vol13/iss1/6>

This Article is brought to you for free and open access by the Undergraduate Research at Knowledge Box. It has been accepted for inclusion in The Corinthian by an authorized editor of Knowledge Box.

Progress Towards A Facile Synthesis of a Gadolinium (III) Octabrominated Porphyrin

Tseng Xiong

Dr. Rosalie Richards
Faculty Sponsor

Abstract

Towards preparing porphyrin complexes that combine contrast agent and photodynamic therapy capabilities at tumor sites, the Gd(III) porphyrin derivative of the octabrominated *meso*-tetrakis(N-methyl-4-pyridyl)porphyrin, GdTMPyPBr₈⁵⁺ was synthesized by refluxing Gd(III) ion with H₃TMPyPBr₈⁵⁺ at pH 7. The metallocomplex was characterized by UV-visible spectroscopy and showed a Soret band shift from 503 nm to 463 nm at pH 7, suggesting that metal insertion of Gd(III) into the core of porphyrin ligand had occurred. However, synthesis of the Gd(III) complex required high temperatures and long reaction times. To circumvent these harsh conditions, the lithium porphyrin derivative was first prepared and subsequently combined with Gd(III) ion to yield the desired product at room temperature.

INTRODUCTION

Cancer is the number two killer in the U.S. just after heart disease. Recent statistics show that 1 in 4 deaths in the United States are due to cancer.¹ Current treatments for cancer and harmful tumors include chemotherapy, radiation, and surgery. However, these treatments are invasive in nature and may produce a number of negative side effects. Photodynamic therapy (PDT), a relatively new mode for cancer treatment, combines a light source and a photosensitizing agent to destroy targeted cells through a photodynamic effect. The photosensitizer is an organic compound that is activated when exposed to light as demonstrated in Figure 1.²

Photodynamic Therapy

Figure 1 shows that exposure of the photosensitizer to light of appropriate wavelengths causes energy transitions from the electronic ground state (S₀) to excited singlet energy states (S₁, etc). The fate of this excited energy depends on the photosensitizer - energy can be emitted as fluorescence (k_f) and in some cases, intersystem crossing (ISC) to triplet excited energy states can result in phosphorescence (k_p). The goal of PDT is for the transfer of excitation energy to molecules such as oxygen to form singlet oxygen (¹O₂) or other reactive species (•O²⁻) that are cytotoxic to cancer and tumor cells.²

Progress Towards A Facile Synthesis of a Gadolinium (III)




Figure 1. Photosensitization of oxygen represented as a Jablonski diagram

The photosensitizing agent in PDT is a critical component of the treatment. Consequently, porphyrins are currently under intense investigation as photosensitizing agents.

Porphyrins and Photodynamic Therapy

Porphyrins are cyclic organic compounds that possess four alternating pyrrole rings and two acidic core protons.³ From a structural perspective, porphyrins are derived from the parent porphyrin “porphine” that is comprised of four alternating pyrrole rings with four methane bridges (Figure 2). Porphyrins consist of 22 π -electrons and 18 contribute to the aromatic system. Porphyrins are highly conjugated systems that strongly absorb visible light. These aromatic macrocycles exhibit a diagnostic optical spectrum due to π - π^* transitions. At approximately 400 nm, porphyrins exhibit an intense Soret band (extinction coefficients $\sim 10^5$ cm⁻¹M⁻¹) and less intense Q-bands between 500 and 700 nm. A key characteristic of porphyrin is that the conjugated structure allows for substitution at the β - and γ -carbons. In addition, metalloporphyrins can be prepared by substitution of metal ions for porphyrin’s core protons.




Figure 2. Porphine structure

Our interest in porphyrins centers on their application as contrast agents in magnetic resonance imaging (MRI) and their potential as photosensitizers in the photodynamic therapy of tumor and cancer cells. Porphyrins absorb visible light strongly and at long wavelengths (> 600 nm) necessary for penetration of photons through deep tissue, they have demonstrated selective accumulation in tumors, low level or dark toxicity, and general lack of severe side effects and disfigurement of patients.⁴ At the same time, Photofrin®, the first porphyrin-based PDT treatment to win approval in the U.S., Canada, Japan, and Europe, has one major limitation – it accumulates in the skin for up to six weeks, rendering patients photosensitive especially to strong sunlight.⁵ Plus, the longest wavelength at which Photofrin® can be photo-activated is 630 nm which is within the general absorption profile of hemoglobin, an abundant pigment in blood. This limits Photofrin's® therapeutic application.

Porphyrins and Magnetic Resonance Imaging Gadolinium(III) Contrast Agents

At present, four non-porphyrinic gadolinium(III) MRI contrast agents have been approved for clinical use since the gadolinium(III) ion provides high quality enhancement of internal images in the human body.⁶ However, Gd(III) contrast agents have been linked to negative health issues such as Nephrogenic Systemic Fibrosis, a rare disease that causes hardening of skin, joints, eyes, and internal organs.⁷ Recent studies suggest that Zn(II), Cu(II), and Ca(II) ions *in vivo* compete for the binding site of the organic ligand to which the Gd(III) ion is bound via a transmetallation reaction that releases the acutely toxic lanthanide ion.⁸ However, other reports demonstrate stability of the metal ion in other porphyrin-based ligands.⁹

MOTIVATION

We recently reported¹⁰ the synthesis of the Gd(III) derivative of a novel

Progress Towards A Facile Synthesis of a Gadolinium (III)

octabrominated water-soluble porphyrin, 2,3,7,8,11,12,17,18-octabromo-meso-tetrakis(N-methyl-4-pyridyl)porphyrin, $H_3TMPyPBr_8^{5+}$ because of our interest in combining the tumor accumulation and photosensitizing properties of porphyrins with the contrast agent enhancement capability of Gd(III) ions. While most porphyrins are near planar, the $H_3TMPyPBr_8^{5+}$ exhibited a saddle-shaped structure with a core that appears large enough to form a stable complex with the large ionic radius of the Gd(III) ion (~108 pm). Although we have successfully synthesized the $GdTMPyPBr_8^{5+}$ complex, reaction at pH 7 required long reflux times (100°C, > 24 h) (equation 1), reducing the cost-effectiveness of the product.



Arnold and others¹⁰ have demonstrated the ease of synthesizing lanthanide porphyrin complexes by reaction between lithium porphyrins and lanthanide ions such as ytterbium(III) ions (equation 2). However, manipulation of these materials required air-sensitive environments.



We were the first to show that a stable mono-lithium complex, $LiTMPyPBr_8^{3+}$, could exist in aqueous basic media (equation 3).¹¹



Therefore, transmetallation of the lithium complex should provide a pathway for the preparation of the Gd(III) porphyrin complex at room temperature (equation 4).




To enhance this reactivity in aqueous and nonaqueous solutions, we recently isolated the air-stable lithium ion porphyrin complex as a red solid at room temperature via metathesis of lithium hexafluorophosphate and the free base octabromoporphyrin.

MATERIALS AND METHODS

Synthesis of $GdTMPyPBr_8^{5+}$ was achieved via reaction of $H_3TMPyPBr_8^{5+}$ and Gd (III) ion using the methods of Richards *et al.*¹⁰ The reaction progress was monitored by UV-visible spectroscopy using a Shimadzu UV2401PC spectrophotometer. *meso*-Tetrakis(N-methyl-4-pyridyl)porphyrin, H_2TMPyP^{4+} , was purchased as the 4-toluenesulfonate (OTs-) salt from Frontier Scientific, Inc. Ammonium hexafluorophosphate (NH_4PF_6), lithium hexafluorophosphate ($LiPF_6$), bromine (Br_2), dimethylformamide (DMF), gadolinium(III) chloride ($GdCl_3$) and acetate ($GdOAc_3$), and tetrabutylammonium chloride (NBu_4Cl) were purchased from Sigma Aldrich. All other reagents, including metal salts, were purchased from Sigma-Aldrich and used without further modification.

Synthesis of $H_3TMPyPBr_8^{5+}$

To 0.239 g (0.175 mmol) of H_2TMPyP^{4+} was added an equimolar quantity of cupric acetate ($Cu(CH_3COO)_2$; 0.0401 g) in 20 mL of methanol. The solution was refluxed for 2 hrs resulting in an initial color change of the solution from purple to dark red (Scheme 1). The mixture was cooled and the solvent removed via distillation. The red solid was collected by suction filtration and air-dried without further purification.



The reaction was monitored by UV-visible spectroscopy (Figure 3).




Figure 3. Absorption spectrum of CuTMPyP₄⁺ (pH 7)

Next, approximately 0.35 g of the product was dissolved in 25 mL DMF. While stirring, 12 mL of Br_2 solution (1 mL Br_2 in 11 mL DMF) was added drop-wise over a time span of 30 minutes. Upon exposure to Br_2 , the solution slowly transitioned from a red solution to a dark green solution and was allowed to stir for an additional 24 hrs as shown in Scheme 2.

Progress Towards A Facile Synthesis of a Gadolinium (III)



Scheme 2. Bromination of CuTMPyP⁴⁺

The resulting solution was vacuum filtered, resulting in a green powder that was air-dried. The product was characterized via UV-Vis spectroscopy (Figure 4).





Figure 4. Absorption spectrum of CuTMPyPBr₈⁴⁺ (pH 7)

The resulting CuTMPyPBr₈⁴⁺ was dissolved in 10 mL of concentrated sulfuric acid to demetallate the Cu(II) ion. The solution changed to a dark brown color and red vapors were evident. After stirring for 30 min, approximately 50 mL of ice was poured into the solution and allowed to stir gently. Once the ice started to melt, excess NH₄PF₆ was added resulting in the formation of a precipitate (Scheme 3). Suction filtration produced a black-brown solid that was washed several times with deionized water and allowed to air-dry overnight.



Scheme 3. Demetallation of Cu(II) ion to prepare $\text{H}_3\text{TMPyPBr}_8^{5+}$
 The product was observed by absorption spectroscopy (Figure 5).





Figure 5. Absorption spectrum of $\text{H}_3\text{TMPyPBr}_8^{5+}$ (pH 7)

Synthesis of GdTMPyPBr_8^{5+}

To 0.352 g of $\text{H}_3\text{TMPyPBr}_8^{5+}$ was added an equimolar GdCl_3 (0.0103g) in 15 mL of water at pH 7. The reaction was refluxed for 24 h and the solution color changed from a black-brown solution to a dark green solution (Scheme 4) as previously reported.

Progress Towards A Facile Synthesis of a Gadolinium (III)



Scheme 4. Synthesis of GdTMPyPBr_8^{5+}

The solution was filtered via suction filtration and the solid was collected and air dried. The absorption spectrum is shown in Figure 6.





Figure 6. Absorption spectrum of target molecule, GdTMPyPBr_8^{5+} (pH 7)


Synthesis of GdTMPyPBr_8^{5+} via LiTMPyPBr_8^{3+}

The LiTMPyPBr_8^{3+} was prepared via metathesis of the deprotonated freebase porphyrin, TMPyPBr_8^{2+} , with lithium ion in basic solution. To a clean glass vial charged with 5 mL of 0.1M NaOH (pH 11) was added approximately 1 mg of the chloride salt of $\text{H}_3\text{TMPyPBr}_8^{5+}$ forming a purple solution (Scheme 5).



Scheme 5. Synthesis of the deprotonated free base porphyrin at pH 11.

Thereafter, the LiTMPyPBr_8^{3+} complex was prepared and isolated as the PF_6^- salt using two different routes. (1) Excess LiCl was added to the basic solution of the TMPyPBr_8^{2+} followed by addition of excess NH_4PF_6 . The solution color immediately changed from purple to red. Formation of the red precipitate was slow ($\sim 1 \text{ h}$). The solid was collected by passing the mixture through a glass pipette plugged with glass wool and air-dried (2). To the basic solution of the TMPyPBr_8^{2+} in 0.1 M NaOH was added excess LiPF_6 . A red solution formed followed immediately by a precipitate. The solid was collected using a glass pipette filtration system and air-dried. The resulting PF_6^- salt was then dissolved in acetone by passing 1 mL aliquots of solvent through the glass-wool charged with dried porphyrin. The solution was collected in a glass vial ($\sim 5 \text{ mL}$) and transformed to the chloride salt by addition of excess $n\text{Bu}_4\text{Cl}$. The resulting precipitate was collected using the glass pipette filtration and air-dried (Scheme 6).



Scheme 6. Synthesis of LiTMPyPBr_8^{3+} under ambient conditions

The absorption spectrum of the LiTMPyPBr_8^{3+} is shown in Figure 7.

Progress Towards A Facile Synthesis of a Gadolinium (III)





Figure 7. Absorption spectra of Li^+ porphyrin derivative (pH 11)

Approximately 2 mg of LiTMPyPB_8^{3+} in 1 mL of pH 7 solution was added to an aqueous solution of GdCl_3 at room temperature. The mixture immediately changed from red to yellow-green. Addition of excess NH_4PF_6 formed a green precipitate that was collected using the glass pipette filtration system. The solid was air-dried (Scheme 7).



Scheme 7. Reaction between Gd(III) ion and LiTMPyPB_8^{3+}

The absorbance showed a Soret band at 455 nm (Figure 8).




Figure 8. Absorbance spectrum of reaction product between Gd(III) ion and LiTMPyPBr₈³⁺ (pH 7)

RESULTS AND DISCUSSION

The project design for a more facile synthesis of the GdTMPyPBr₈⁵⁺ was based on a transmetallation reaction between the lithium porphyrin derivative and Gd(III) ion which was a modified reaction approach to our previous report on the synthesis of GdTMPyPBr₈⁵⁺.¹⁰ To advance this reactivity, the LiTMPyPBr₈³⁺ precursor was prepared using a multistep synthetic scheme.

Table I demonstrates that bromination of the starting material, H₂TMPyP⁴⁺, resulted in the shift of the porphyrin absorption spectrum from 425 nm to 503 nm. Deprotonation of H₃TMPyPBr₈⁵⁺ in aqueous base resulted in the purple TMPyPBr₈²⁺ species presumably due to delocalization of the negative charges at the core nitrogen atoms and solvation of the dianionic species in polar solvent. Subsequent metallation with lithium ion transformed the color from purple to pink, consistent with previous studies using curve-fitting analyses and ⁷Li NMR that established the formation of a mono-lithium porphyrin species.¹² Bromination was likely required for the subsequent insertion of the Gd(III) ion since β-substitution afforded a saddle-shaped macrocycle with a core large enough to bind the Gd(III) ion.

Progress Towards A Facile Synthesis of a Gadolinium (III)

Table I: Absorption spectral data of synthesized porphyrins and metal derivatives

Porphyrin	λ_{max} (nm; pH 7)	Color
H ₂ TMPyP ⁴⁺	425	red
CuTMPyP ⁴⁺	425	red
CuTMPyPBr ₈ ⁴⁺	457	green
H ₃ TMPyPBr ₈ ⁵⁺	503	brown-black
TMPyPBr ₈ ²⁺	579	purple
LiTMPyPBr ₈ ³⁺	530-538	red-pink
GdTMPyPBr ₈ ⁵⁺	455-463	green

The UV-visible spectrum of the reaction product between the lithium porphyrin derivative and Gd(III) ion was consistent with our findings for the synthesis of GdTMPyPBr₈⁵⁺ and resembled the absorption profile of transition metal derivatives of the H₃TMPyPBr₈⁵⁺.¹³ Our preliminary results indicate that we can efficiently prepare and use the LiTMPyPBr₈³⁺ as a precursor for transition metal ion complexes and the Gd(III) porphyrin.

CONCLUSIONS AND OUTLOOK

We plan to further characterize the Gd(III) complex via NMR spectroscopy and powder diffraction analysis. Thereafter, the photophysical properties of the GdTMPyPBr₈⁵⁺ will be investigated to determine its interaction with dioxygen. A scale-up of the LiTMPyPBr₈³⁺ product as the solid hexafluorophosphate salt was confounded during the precipitation stage, presumably due to reactivity of the anion in aqueous base. Therefore, this reaction will be revisited.

ACKNOWLEDGEMENTS

T.X. would like to acknowledge the Department of Chemistry, Physics, and Astronomy Chemistry Scholars Program and the Young Scientists Academy and the Science Education Center at Georgia College for research support. T.S. gratefully acknowledges research support from the Kaolin Science Education Endowment at Georgia College. G.J. is grateful for support from the Young Scientists Academy at Georgia College and the Georgia Military College Bull Dog Club. C.J. would like to acknowledge the American Chemical Society Project SEED summer research program and the Middle Georgia Section of the American Chemical Society for funding. R.A.R. gratefully acknowledges funding from the Faculty Research Grant program at Georgia College.

REFERENCES

1. Jemal, Ahmadian; Siegel, Rebecca; Xu Jiaquan. Cancer Statistics, 2010. *A Cancer Journal for Clinicians*. 60, 5, 277-300.
2. *Porphyrin-based Photosensitizers for Use in Photodynamic Therapy*. Sternberg, E. D.; Dolphin, D.; Brickner, C. *Tetrahedron* **1998**, 54, 4151-4202.
3. Kadish, K.M.; Smith, K.M.; Guillard, R., Eds. *The Porphyrin Handbook, Vol.1, Synthesis and Organic Chemistry*. Academic Press: New York, NY, 2000.
4. Kadish, K.M.; Smith, K.M.; Guillard, R., Eds. *The Porphyrin Handbook, Vol. 6, Applications: Past, Present, and Future*. Academic Press: New York, NY, 2000.
5. Adler, A.D. *The Chemical and Physical Behavior of Porphyrin Compounds and Related Structures*; New York Academy of Sciences: New York, NY, 1973.
6. (a) Goldman, M.P. *Photodynamic Therapy: Information on Gadolinium-Containing Contrast Agents*. Elsevier Science: Philadelphia, PA, 2005. (b) Stark, D.D.; Bradley, W.G. *Magnetic Resonance Imaging*; C.V. Mosbey: New York, NY, 1988.
7. Information for Healthcare Professional. Gadolinium-Containing Contrast Agents for Magnetic Resonance Imaging. U.S. Food and Drug Administration. <http://www.fda.gov/ederdrug/infopage/gcca/default.htm>. (accessed October 20,2011)
8. *Gd(III)-Based Contrast Agents for MRI*. Aime, S.; Botta, M.; Terreno, E. *Adv. Inorg. Chem.* **2005**, 57, 173-237.
9. (a) *Porphyrin-based Sensitizers in the Detection and Treatment of Cancer: Recent Progress*. Vicente, M.G.H. *Current Medicinal Chemistry - Anti-Cancer Agents*. **2001**, 1, 175-194. (b) Motexafin Gadolinium Cancer Treatment Product Candidate. 2008. Pharmacyclics. <http://www.pharmacyclics.com/wt/page/xcytrin>. (accessed October 19, 2011).
10. *Synthesis of a Novel Gadolinium (III) Porphyrin as a Contrast Agent and Photosensitizer in Tumors*. Owens, J. H.; Richards, R. A. *The Corinthian*. **2009**, 10, 407-420.
11. (a) *Synthesis and characterization of lithium, sodium, and potassium porphyrin complexes. X-ray crystal structures of $\text{Li}_2(\text{C}_6\text{H}_{12}\text{O}_2)_2\text{TMPP}$, $\text{Na}_2(\text{THF})_4\text{OEP}$, and $\text{K}_2(\text{pyridine})_4\text{OEP}$* . Arnold, J.; Dawson, D.; Hoffman, C. *J. Am. Chem. Soc.* **1993**, 115, 2707-2713. (b) *New Lithium Porphyrin Derivatives: Synthesis of $\text{Li}_2(\text{P})(\text{Et}_2\text{O})_2$ ($\text{P} = \text{TTP, TBPP}$) and Solution Structure of $\text{Li}_2(\text{TTP})(\text{Et}_2\text{O})_2$ by ^7Li and ^{15}N*

Progress Towards A Facile Synthesis of a Gadolinium (III)

- NMR. Brand, H.; Capriotti, J. A.; Arnold, J. *Inorg. Chem.* **1994**, 33 4334–4337. (c) *Metal Complexes with Tetrapyrrole Ligands, LIX – Redox Potentials, Near-Infrared Absorption, Ionic Radii, and Ring-Ring Distance in Metal(III) Bis(tetraphenylporphyrinate) Systems with Porphyrin Rings in Different Oxidation States.* Buchler, J.W.; Hiittermann, J.; Loffler, J. *Bull. Soc. Chem. Jpn.* **1988**, 61, 71-77. (d) *Lithium complexes and the kinetics of interactions of zinc ions with tetra(N-methyl-4-pyridyl) porphyrins in basic solution.* Islam, M. Q.; Hambright, P. *Trans. Met. Chem.* **1998**, 23, 727-733.
12. (a) Rosalie, R.; Hammons, K.; Joe, M.; Miskelly, G. M. *Observation of a Soluble Water-Soluble Lithium Porphyrin.* *Inorg. Chem.*, **1996**, 35, 1940-1944. (b) Jadol, G; Debesai, K; Shoman, T; Rosalie, R. *Air-stable lithium porphyrin intermediates: Pathways to metallocomplexes. Paper presented at the Sixth International Conference on Porphyrins & Phthalocyanines, Albuquerque, New Mexico. July 4-9, 2010.*
13. Richards, R; Miskelly, G., Unpublished results.